Join Talphera for a virtual investor and analyst event featuring Blaithin McMahon, PhD, MBBChr (Medical University of South Carolina) and Joao Teixeira, MD (University of New Mexico), principal investigators in Talphera’s NEPHRO CRRT study evaluating Niyad^TM for continuous renal replacement therapy (CRRT).

The experts will discuss their experience with CRRT, the anticoagulants being used during CRRT today, and how they see Talphera’s nafamostat filling a need. Nafamostat is a serine protease inhibitor with anticoagulant, anti-inflammatory, and potential antiviral properties with a variety of applications in medically supervised settings and has been the standard of care for CRRT anticoagulation in Japan and South Korea for over three decades. The Company’s lead product candidate, Niyad™, a lyophilized form of nafamostat, leverages the ultrashort half-life of nafamostat and its potent anticoagulant effects for potential use as a regional anticoagulant during CRRT in patients who cannot tolerate heparin or who have an increased risk of bleeding. Heparin is the only FDA approved anticoagulant for use in CRRT but it is not safe for patients with a high risk of bleeding or heparin intolerance. Citrate, the only other anticoagulant being used for CRRT, is used off-label, is complex to administer, cannot be used in liver impaired patients, and is principally used by large academic institutions with the resources to monitor administration.

A live question and answer session will follow the formal presentations.